Nabizadeh Fardin
School of Medicine, Iran University of Medical Sciences, Tehran, 1449614535, Iran.
Brain Commun. 2023 Oct 24;5(6):fcad286. doi: 10.1093/braincomms/fcad286. eCollection 2023.
Triggering Receptor Expressed on Myeloid Cell 2 (TREM2) plays a crucial role in the transition of microglia from a state of homeostasis to a state associated with the disease. Mutations in TREM2 are strongly linked with a higher risk of developing neurodegenerative diseases, including Alzheimer's disease. There have been contradictory findings regarding the potential detrimental or protective effects of microglial activation and TREM2-related microglial responses in Alzheimer's disease. Although previous studies reported increased CSF soluble TREM2 (sTREM2) in different clinical stages of Alzheimer's disease, the exact association between Alzheimer's disease hallmarks such as amyloid-beta and tau pathology remains unclear. In the present study, I aimed to investigate the association between TREM2-related microglial responses and tau accumulation in the presence and absence of amyloid-beta pathology in order to give a better view of the role of microglial activation in Alzheimer's disease development. Imaging data of 178 non-demented participants including 107 amyloid-beta-negative participants, 71 amyloid-beta-positive were recruited from Alzheimer's disease Neuroimaging Initiative. The CSF sTREM2 was used as an indicator of microglial responses associated with TREM2. Furthermore, I used longitudinal tau-PET and resting-state functional MRI connectomes in order to investigate the association of TREM2-related microglial activation and tau spreading through functional connections. A higher level of sTREM2 was associated with slower tau aggregate accumulation in non-demented amyloid-beta-positive. Furthermore, measuring the tau spreading through inter-connected regions using functional MRI connectomes confirms that the TREM2-related microglial activity might be a protective factor against tau pathology in brain tissue. These findings demonstrate that in individuals with initial amyloid-beta abnormalities, TREM2-related microglial activation is linked to reduced regional accumulation of tau aggregates and also, spreading across inter-connected brain regions, as evaluated through functional MRI connectomes during the early stages of Alzheimer's disease.
髓系细胞触发受体2(TREM2)在小胶质细胞从稳态向疾病相关状态的转变中起关键作用。TREM2突变与包括阿尔茨海默病在内的神经退行性疾病的高发病风险密切相关。关于小胶质细胞激活和TREM2相关小胶质细胞反应在阿尔茨海默病中的潜在有害或保护作用,存在相互矛盾的研究结果。尽管先前的研究报告称,在阿尔茨海默病的不同临床阶段,脑脊液中可溶性TREM2(sTREM2)水平升高,但阿尔茨海默病标志性病变如β-淀粉样蛋白和tau病理之间的确切关联仍不清楚。在本研究中,我旨在调查在有或没有β-淀粉样蛋白病理的情况下,TREM2相关小胶质细胞反应与tau积累之间的关联,以便更好地了解小胶质细胞激活在阿尔茨海默病发展中的作用。从阿尔茨海默病神经影像倡议组织招募了178名非痴呆参与者的影像数据,其中包括107名β-淀粉样蛋白阴性参与者和71名β-淀粉样蛋白阳性参与者。脑脊液sTREM2被用作与TREM2相关的小胶质细胞反应的指标。此外,我使用纵向tau-PET和静息态功能MRI连接组,以研究TREM2相关小胶质细胞激活与通过功能连接的tau扩散之间的关联。在非痴呆的β-淀粉样蛋白阳性个体中,较高水平的sTREM2与tau聚集体积累较慢相关。此外,使用功能MRI连接组测量通过相互连接区域的tau扩散证实,TREM2相关的小胶质细胞活动可能是脑组织中tau病理的保护因素。这些发现表明,在最初有β-淀粉样蛋白异常的个体中,TREM2相关的小胶质细胞激活与tau聚集体的区域积累减少有关,并且在阿尔茨海默病早期通过功能MRI连接组评估,还与跨相互连接的脑区扩散有关。